Recent Updates
Recently added Catalysts
QURE Negative Sentiment Score: 25/100

uniQure N.V. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before April 13, 2026 to Discuss Your Rights – QURE

Key Takeaway: uniQure N.V. has been sued for securities law violations based on allegations that the company made materially false statements regarding its clinical trial results and the approval status of its study design by the FDA. The lawsuit also suggests that uniQure did not adequately disclose the potential delays in its Biologics License Application timeline due to the need for additional studies. Shareholders who purchased stock during the specified period are encouraged to contact the Gross Law Firm for potential recovery options.

Market Sentiment Analysis

CONCERNS & RISKS

  • uniQure is facing a lawsuit for allegedly issuing misleading statements regarding its Pivotal Study design approval by the FDA.
  • The lawsuit claims that uniQure downplayed the likelihood of delays in its Biologics License Application timeline due to incomplete studies.
  • Defendants' statements about the company's business and prospects are said to lack a reasonable basis, raising concerns about investor transparency.

Full Press Release Details

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE).
Shareholders who purchased shares of QURE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: September 24, 2025 to October 31, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the design of uniQure’s Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; (2) defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License Application (“BLA”) timeline to perform additional studies to supplement its BLA submission; and (3) as a result, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
DEADLINE: April 13, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/uniqure-loss-submission-form/?id=184121&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of QURE during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 13, 2026. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for uniQure N.V. shareholders?

The class period for shareholders is from September 24, 2025, to October 31, 2025.

How can I register for the class action regarding uniQure N.V.?

You can register for the class action by visiting the provided link for submissions.

What are the allegations against uniQure N.V.?

The allegations include misleading statements regarding FDA approval and study results.

Is there a deadline to become a lead plaintiff?

Yes, the deadline to seek lead plaintiff status is April 13, 2026.

Is there a cost to participate in the uniQure class action?

There is no cost or obligation to participate in the class action case.

Last updated: Mar 6, 2026